FIBROGEN INC (FGEN) Stock Fundamental Analysis
USA - NASDAQ:FGEN - US31572Q8814 - Common Stock
8.42 USD
+0.12 (+1.45%)
Taking everything into account, FGEN scores 2 out of 10 in our fundamental rating. FGEN was compared to 533 industry peers in the Biotechnology industry. FGEN has a bad profitability rating. Also its financial health evaluation is rather negative. FGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year FGEN was profitable.
In the past year FGEN has reported a negative cash flow from operations.
FGEN had negative earnings in each of the past 5 years.
In the past 5 years FGEN reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.16%, FGEN belongs to the top of the industry, outperforming 89.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.16% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FGEN has a Gross Margin of 128.07%. This is amongst the best in the industry. FGEN outperforms 99.06% of its industry peers.
FGEN's Gross Margin has declined in the last couple of years.
FGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 128.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
2. Health
2.1 Basic Checks
FGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FGEN has been increased compared to 1 year ago.
FGEN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for FGEN is higher compared to a year ago.
2.2 Solvency
FGEN has an Altman-Z score of -16.63. This is a bad value and indicates that FGEN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of FGEN (-16.63) is worse than 82.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.63 |
ROIC/WACCN/A
WACC14.63%
2.3 Liquidity
A Current Ratio of 1.04 indicates that FGEN should not have too much problems paying its short term obligations.
The Current ratio of FGEN (1.04) is worse than 87.05% of its industry peers.
FGEN has a Quick Ratio of 1.02. This is a normal value and indicates that FGEN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.02, FGEN is doing worse than 86.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 102.02% over the past year.
FGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -36.71%.
FGEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -35.07% yearly.
EPS 1Y (TTM)102.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)-36.71%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.68%
3.2 Future
The Earnings Per Share is expected to grow by 15.11% on average over the next years. This is quite good.
The Revenue is expected to grow by 9.58% on average over the next years. This is quite good.
EPS Next Y52.49%
EPS Next 2Y-13.35%
EPS Next 3Y-4.37%
EPS Next 5Y15.11%
Revenue Next Year-96.23%
Revenue Next 2Y-81.07%
Revenue Next 3Y-67.04%
Revenue Next 5Y9.58%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.58 indicates a correct valuation of FGEN.
Based on the Price/Earnings ratio, FGEN is valued cheaply inside the industry as 96.06% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of FGEN to the average of the S&P500 Index (25.45), we can say FGEN is valued slightly cheaper.
FGEN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.58 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as FGEN's earnings are expected to decrease with -4.37% in the coming years.
PEG (NY)0.26
PEG (5Y)N/A
EPS Next 2Y-13.35%
EPS Next 3Y-4.37%
5. Dividend
5.1 Amount
No dividends for FGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:FGEN (11/21/2025, 8:00:01 PM)
8.42
+0.12 (+1.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners26.49%
Inst Owner Change3.06%
Ins Owners1.41%
Ins Owner Change-0.02%
Market Cap34.02M
Revenue(TTM)29.62M
Net Income(TTM)-2.07M
Analysts80
Price Target43.86 (420.9%)
Short Float %2.63%
Short Ratio3.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)82.57%
Min EPS beat(2)20.04%
Max EPS beat(2)145.1%
EPS beat(4)4
Avg EPS beat(4)109.14%
Min EPS beat(4)20.04%
Max EPS beat(4)226.05%
EPS beat(8)7
Avg EPS beat(8)63%
EPS beat(12)8
Avg EPS beat(12)40.12%
EPS beat(16)11
Avg EPS beat(16)583.04%
Revenue beat(2)1
Avg Revenue beat(2)14.05%
Min Revenue beat(2)-49.76%
Max Revenue beat(2)77.86%
Revenue beat(4)3
Avg Revenue beat(4)39.29%
Min Revenue beat(4)-49.76%
Max Revenue beat(4)98.39%
Revenue beat(8)6
Avg Revenue beat(8)28.13%
Revenue beat(12)9
Avg Revenue beat(12)20.88%
Revenue beat(16)11
Avg Revenue beat(16)17.71%
PT rev (1m)0%
PT rev (3m)-82.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-54.63%
EPS NY rev (1m)0%
EPS NY rev (3m)53.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-43.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-32.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.58 | ||
| Fwd PE | N/A | ||
| P/S | 0.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)0.62
EY7.36%
EPS(NY)-15.42
Fwd EYN/A
FCF(TTM)-5.86
FCFYN/A
OCF(TTM)-5.8
OCFYN/A
SpS13.26
BVpS-55.2
TBVpS-55.2
PEG (NY)0.26
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.16% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 128.07% | ||
| FCFM | N/A |
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
F-Score3
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15.38% | ||
| Cap/Sales | 0.47% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | -16.63 |
F-Score3
WACC14.63%
ROIC/WACCN/A
Cap/Depr(3y)133.57%
Cap/Depr(5y)124.53%
Cap/Sales(3y)11.27%
Cap/Sales(5y)9.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y52.49%
EPS Next 2Y-13.35%
EPS Next 3Y-4.37%
EPS Next 5Y15.11%
Revenue 1Y (TTM)-36.71%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.68%
Revenue Next Year-96.23%
Revenue Next 2Y-81.07%
Revenue Next 3Y-67.04%
Revenue Next 5Y9.58%
EBIT growth 1Y21.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.35%
EBIT Next 3Y3.31%
EBIT Next 5Y0.07%
FCF growth 1Y92.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.59%
OCF growth 3YN/A
OCF growth 5YN/A
FIBROGEN INC / FGEN FAQ
What is the ChartMill fundamental rating of FIBROGEN INC (FGEN) stock?
ChartMill assigns a fundamental rating of 2 / 10 to FGEN.
Can you provide the valuation status for FIBROGEN INC?
ChartMill assigns a valuation rating of 3 / 10 to FIBROGEN INC (FGEN). This can be considered as Overvalued.
What is the profitability of FGEN stock?
FIBROGEN INC (FGEN) has a profitability rating of 2 / 10.
What is the financial health of FIBROGEN INC (FGEN) stock?
The financial health rating of FIBROGEN INC (FGEN) is 1 / 10.
What is the earnings growth outlook for FIBROGEN INC?
The Earnings per Share (EPS) of FIBROGEN INC (FGEN) is expected to grow by 52.49% in the next year.